JP5694668B2 - 自己免疫疾患の診断上および治療上の標的ならびにその用途 - Google Patents

自己免疫疾患の診断上および治療上の標的ならびにその用途 Download PDF

Info

Publication number
JP5694668B2
JP5694668B2 JP2009544308A JP2009544308A JP5694668B2 JP 5694668 B2 JP5694668 B2 JP 5694668B2 JP 2009544308 A JP2009544308 A JP 2009544308A JP 2009544308 A JP2009544308 A JP 2009544308A JP 5694668 B2 JP5694668 B2 JP 5694668B2
Authority
JP
Japan
Prior art keywords
znt8
antibody
protein
fragment
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009544308A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010514805A (ja
JP2010514805A5 (enExample
Inventor
シー． ハットン、ジョン
シー． ハットン、ジョン
エム． ウェンツロウ、ジャネット
エム． ウェンツロウ、ジャネット
ジェンセン、ジャン
デイビッドソン、ハワード
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado System
Original Assignee
University of Colorado System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Colorado System filed Critical University of Colorado System
Publication of JP2010514805A publication Critical patent/JP2010514805A/ja
Publication of JP2010514805A5 publication Critical patent/JP2010514805A5/ja
Application granted granted Critical
Publication of JP5694668B2 publication Critical patent/JP5694668B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Rehabilitation Therapy (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
JP2009544308A 2006-12-29 2007-12-28 自己免疫疾患の診断上および治療上の標的ならびにその用途 Active JP5694668B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88281506P 2006-12-29 2006-12-29
US60/882,815 2006-12-29
PCT/US2007/089125 WO2008083331A2 (en) 2006-12-29 2007-12-28 Diagnostic and therapeutic target for autoimmune diseases and uses thereof

Publications (3)

Publication Number Publication Date
JP2010514805A JP2010514805A (ja) 2010-05-06
JP2010514805A5 JP2010514805A5 (enExample) 2010-11-25
JP5694668B2 true JP5694668B2 (ja) 2015-04-01

Family

ID=39589229

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009544308A Active JP5694668B2 (ja) 2006-12-29 2007-12-28 自己免疫疾患の診断上および治療上の標的ならびにその用途

Country Status (8)

Country Link
US (1) US9023984B2 (enExample)
EP (1) EP2118309B1 (enExample)
JP (1) JP5694668B2 (enExample)
CN (1) CN101646781B (enExample)
DK (1) DK2118309T3 (enExample)
ES (1) ES2533566T3 (enExample)
PL (1) PL2118309T3 (enExample)
WO (1) WO2008083331A2 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2486122A (en) * 2009-09-18 2012-06-06 Univ California Methods for detecting autodigestion
CN102060910B (zh) * 2010-11-12 2012-11-21 中国人民解放军第三军医大学 锌转运蛋白8的hla-a＊0201限制性ctl表位及其应用
KR20250020688A (ko) * 2011-04-29 2025-02-11 셀렉타 바이오사이언시즈, 인크. 항체 반응을 감소시키기 위한 관용원성 합성 나노운반체
US20140271701A1 (en) 2011-10-26 2014-09-18 Universita' Degli Studi Di Sassari Use of mycobacterium avium paratuberculosis peptides to diagnose type 1 diabetes
CN103177198B (zh) * 2011-12-26 2016-11-23 深圳华大基因科技服务有限公司 一种蛋白质鉴定方法
IN2014DN09410A (enExample) 2012-04-13 2015-07-17 Diabetomics Llc
CN102967704B (zh) * 2012-11-26 2014-05-14 深圳市伯劳特生物制品有限公司 一种用于糖尿病自身抗体6项联检试剂盒
US20160025744A1 (en) * 2013-03-14 2016-01-28 The Board Of Trustees Of The Leland Stanford Junior University Plasmonic substrate for multiplex assessment of type 1 diabetes
MX2021005697A (es) 2013-05-03 2021-07-07 Selecta Biosciences Inc Suministro de inmunosupresores que tienen una vida efectiva especificada, farmacodinamica y antigeno para la induccion de tolerancia inmunitaria.
KR102523912B1 (ko) 2013-06-11 2023-04-21 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 SC-β 세포 및 조성물 그리고 그 생성 방법
CN106535926B (zh) * 2014-06-04 2022-02-01 戴尔米德医疗公司 用于基于抗原的疗法的新型组合物
KR101482908B1 (ko) 2014-07-25 2015-01-15 충남대학교산학협력단 간질중첩증 진단용 바이오마커 조성물
CN106714826A (zh) 2014-09-07 2017-05-24 西莱克塔生物科技公司 用于减弱基因表达调节抗病毒转移载体免疫应答的方法和组合物
EP4374863A3 (en) 2014-12-18 2024-09-04 President and Fellows of Harvard College Methods for generating stem cell-derived beta cells and uses thereof
CN113234661A (zh) 2014-12-18 2021-08-10 哈佛学院校长同事会 干细胞来源的β细胞的产生方法及其使用方法
US10443042B2 (en) 2014-12-18 2019-10-15 President And Fellows Of Harvard College Serum-free in vitro directed differentiation protocol for generating stem cell-derived beta cells and uses thereof
GB201510056D0 (en) * 2015-06-10 2015-07-22 King S College London Multi-peptide composition
US10542961B2 (en) 2015-06-15 2020-01-28 The Research Foundation For The State University Of New York System and method for infrasonic cardiac monitoring
US20170082619A1 (en) 2015-09-23 2017-03-23 One Lambda, Inc. Methods of Detecting Alloantibodies Using HLA and Non-HLA Antigens
CN106084051B (zh) * 2016-02-17 2018-03-02 张梅 一种ZnT8特异性单链抗体scFv‑C27及其应用
CN106084043B (zh) * 2016-02-17 2018-03-02 张梅 一种ZnT8特异性单链抗体scFv‑C22及其应用
WO2017189483A1 (en) 2016-04-25 2017-11-02 The Johns Hopkins University Znt8 assays for drug development and pharmaceutical compositions
CN106771233A (zh) * 2016-12-05 2017-05-31 上海良润生物医药科技有限公司 ZnT8A自身抗体检测试剂盒
CN110612122A (zh) 2017-03-11 2019-12-24 西莱克塔生物科技公司 与用抗炎剂和包含免疫抑制剂之合成纳米载体进行的组合治疗相关的方法和组合物
US11892457B2 (en) 2017-07-12 2024-02-06 The Johns Hopkins University Proteoliposome-based ZnT8 self-antigen for type 1 diabetes diagnosis
MX2020004939A (es) 2017-11-15 2020-11-11 Semma Therapeutics Inc Fabricacion de composiciones de celulas islote y metodos de uso de las mismas.
CN108414766A (zh) * 2018-01-29 2018-08-17 上海良润生物医药科技有限公司 用于定量检测糖尿病自身抗体的试剂盒及其应用
AU2019320072A1 (en) 2018-08-10 2021-02-25 Vertex Pharmaceuticals Incorporated Stem cell derived islet differentiation
EP3837286A4 (en) 2018-08-16 2022-08-10 The Johns Hopkins University ANTIBODIES TO HUMAN ZNT8
CN109628462B (zh) * 2018-12-13 2021-02-19 宁波大学 一种水稻根系伸长控制基因OsKSR7及编码的蛋白质
CN109734793B (zh) * 2019-03-14 2022-12-02 深圳市药品检验研究院（深圳市医疗器械检测中心） 一种ZnT8重组蛋白及其制备方法和应用
US12366570B2 (en) 2019-10-01 2025-07-22 The Johns Hopkins University Cell-based ZNT8 assay
CN111579791A (zh) * 2020-04-30 2020-08-25 江苏省人民医院（南京医科大学第一附属医院） 一种锌转运体8胰岛自身抗体的电化学发光检测试剂盒
CN113999841A (zh) * 2021-09-16 2022-02-01 江苏省人民医院（南京医科大学第一附属医院） 蛋白质支架oval100及其在放射配体法中的应用
CN116589589B (zh) * 2023-03-24 2024-10-22 深圳市昭蓝生物科技有限公司 糖尿病检测的质控品及其制备方法和用途
CN117031014A (zh) * 2023-08-14 2023-11-10 陕西脉元生物科技有限公司 抗matr3自身抗体的试剂在制备检测神经系统自身免疫疾病的产品中的应用及试剂盒
CN120714599B (zh) * 2025-08-28 2025-10-31 江苏集萃医工交叉技术研究所有限公司 一种血清bicc1天然蛋白的高效提取保存方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
CA2043472A1 (en) 1990-06-04 1991-12-05 Mitsutaka Miyabayashi Electrode for secondary battery
US5820866A (en) * 1994-03-04 1998-10-13 National Jewish Center For Immunology And Respiratory Medicine Product and process for T cell regulation
US20020082207A1 (en) 2000-06-07 2002-06-27 Hirst Shannon K. Compositions and methods for the therapy and diagnosis of pancreatic cancer
FR2847263B1 (fr) 2002-11-18 2006-01-13 Commissariat Energie Atomique Polynucleotide specifique de la cellule pancreatique beta des ilots de langerhans

Also Published As

Publication number Publication date
ES2533566T3 (es) 2015-04-13
PL2118309T3 (pl) 2015-07-31
EP2118309B1 (en) 2015-01-28
US9023984B2 (en) 2015-05-05
DK2118309T3 (en) 2015-03-30
JP2010514805A (ja) 2010-05-06
WO2008083331A2 (en) 2008-07-10
EP2118309A4 (en) 2010-06-02
CN101646781B (zh) 2016-06-22
WO2008083331A3 (en) 2008-11-13
CN101646781A (zh) 2010-02-10
US20100143374A1 (en) 2010-06-10
EP2118309A2 (en) 2009-11-18

Similar Documents

Publication Publication Date Title
JP5694668B2 (ja) 自己免疫疾患の診断上および治療上の標的ならびにその用途
Alimohammadi et al. Autoimmune polyendocrine syndrome type 1 and NALP5, a parathyroid autoantigen
Lampasona et al. Islet autoantibodies
Roth et al. Anti–LAMP-2 antibodies are not prevalent in patients with antineutrophil cytoplasmic autoantibody glomerulonephritis
Lernmark Glutamic acid decarboxylase–gene to antigen to disease
Towns et al. GAD65 autoantibodies and its role as biomarker of Type 1 diabetes and Latent Autoimmune Diabetes in Adults (LADA)
US20080038269A1 (en) Methods for detecting and treating kidney disease
Miao et al. Role of autoantibodies in type 1 diabetes
JP2018197236A (ja) 修飾型自己エピトープに対する抗腫瘍免疫応答
JP2013535963A (ja) Ｍｈｃクラスｉｉと糖尿病関連自己抗原性ペプチドとの天然型複合体に対するｔ細胞受容体様特異性を有する単離された高親和性実体
WO2007110230A2 (en) Secreted proteins as early markers and drug targets for autoimmunity, tumorigenesis and infections
Nayak et al. ZnT8-reactive T cells are weakly pathogenic in NOD mice but can participate in diabetes under inflammatory conditions
Rackaityte et al. Validation of a murine proteome-wide phage display library for the identification of autoantibody specificities
US10024854B2 (en) Method for detecting and purifying pancreatic beta cells
Kelemen et al. HLA-DQ8-associated T cell responses to the diabetes autoantigen phogrin (IA-2β) in human prediabetes
JP2018517151A (ja) 関節リウマチの診断のための自己抗原
AU2004284020A1 (en) Peptides with anti-obesity activity and other related uses
WO2021138273A2 (en) Autoantibodies as biomarkers for autoimmune polyglandular syndrome type 1
Flynn et al. Superiority of thyroid peroxidase DNA over protein immunization in replicating human thyroid autoimmunity in HLA-DRB1* 0301 (DR3) transgenic mice
US20060014941A1 (en) Isolated T lymphocyte receptors specific for human autoantigens complexed with human MHC molecules and methods of making and using same
Weenink et al. Autoantibodies in diabetes
WO2008066483A1 (en) Use of nalp5 in methods for diagnosis and therapy of parathyroid related disorders
Yang et al. Mapping I-Ag7 restricted epitopes in murine G6PC2
Batstra Prediction of type-1 diabetes: evaluation of assays for ß-cell antibodies
Abreu et al. Autoreactive CD8. sup.+ T cells in Type 1 diabetes: implications for pathogenesis, diagnosis, disease progression and therapeutic intervention

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101008

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101008

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130702

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140707

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150120

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150205

R150 Certificate of patent or registration of utility model

Ref document number: 5694668

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250